Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RGNX Regenxbio

Closed 02-09 16:00:00 EST

10.31

-0.02

-0.19%

盘后8.50

-1.81-17.54%

19:59 EST

High10.62	Low10.01	Vol955.42K
Open10.14	D1 Closing10.33	Amplitude5.91%
Mkt Cap521.92M	Tradable Cap427.07M	Total Shares50.62M
T/O9.86M	T/O Rate2.31%	Tradable Shares41.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio","latestPrice":10.31,"timestamp":1770670800000,"preClose":10.33,"halted":0,"volume":955423,"hourTrading":{"tag":"盘后","latestPrice":8.5014,"preClose":10.31,"latestTime":"19:59 EST","volume":310831,"amount":2521696.2427,"timestamp":1770685185382,"change":-1.8086,"changeRate":-0.175422,"amplitude":0.306499},"delay":0,"changeRate":-0.0019361084220715947,"floatShares":41423137,"shares":50623086,"eps":-3.46438,"marketStatus":"Closed","change":-0.02,"latestTime":"02-09 16:00:00 EST","open":10.14,"high":10.62,"low":10.01,"amount":9855350.66691,"amplitude":0.059051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.46438,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":10.33,"preHourTrading":{"tag":"盘前","latestPrice":10.37,"preClose":10.33,"latestTime":"09:20 EST","volume":8671,"amount":90964.668938,"timestamp":1770646818256,"change":0.04,"changeRate":0.003872,"amplitude":0.058083},"postHourTrading":{"tag":"盘后","latestPrice":8.5014,"preClose":10.31,"latestTime":"19:59 EST","volume":310831,"amount":2521696.2427,"timestamp":1770685185382,"change":-1.8086,"changeRate":-0.175422,"amplitude":0.306499},"volumeRatio":1.12518,"impliedVol":0.9498,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/RGNX/tweets","defaultTab":"tweets","newsList":[{"id":"2610647667","title":"Regenxbio price target lowered to $45 from $50 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610647667?lang=en_us&edition=fundamental","pubTime":"2026-02-10 07:50","pubTimestamp":1770681017,"startTime":"0","endTime":"0","summary":"Clear Street lowered the firm’s price target on Regenxbio (RGNX) to $45 from $50 and keeps a Buy rating on the shares. The firm cites the FDA havin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-45-from-50-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-45-from-50-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX"],"gpt_icon":0},{"id":"2610966235","title":"Stocks to Watch: Goodyear Tire, On Semiconductor, RegenexBio, Upwork","url":"https://stock-news.laohu8.com/highlight/detail?id=2610966235","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610966235?lang=en_us&edition=fundamental","pubTime":"2026-02-10 07:07","pubTimestamp":1770678420,"startTime":"0","endTime":"0","summary":"Goodyear Tire & Rubber logged lower-than-expected adjusted earnings as the company continues to face challenging industry dynamics. Shares fell 9% to $9.54 in after-hours trading on Monday.On Semiconductor's revenue fell in the fourth quarter due to weakness in two of its business units. The stock declined 4.8% to $62.00 after the bell.RegenxBio said the FDA didn't approve its gene therapy RGX-121. Shares dropped 16.6% to $8.60.Upwork's first-quarter outlook came in below Wall Street expectations. The stock slid 24.3% to $14.23.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0724618433.USD","BK4588","IE00BZ199S13.USD","LU1861215975.USD","LU1720051017.SGD","UPWK","LU1861214812.USD","LU1861220033.SGD","LU1854103824.USD","LU2360107325.USD","LU2298322129.HKD","IE00BFMHRM44.USD","BK4512","LU0124384867.USD","BK4505","BK4585","BK4130","LU1861219969.SGD","LU1548497426.USD","LU1854104046.USD","LU0348723411.USD","BK4139","BK4141","IE00BD6J9T35.USD","BK4563","BK4119","RGNX","LU2357305700.SGD","ON","LU1720051108.HKD","LU1978683503.SGD","BK4605","GT"],"gpt_icon":0},{"id":"2610664455","title":"Regenxbio's Gene Therapy for Hunter Syndrome Fails to Win FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2610664455","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610664455?lang=en_us&edition=fundamental","pubTime":"2026-02-10 06:47","pubTimestamp":1770677230,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) said late Monday the US Food and Drug Administration did not approve its biologics license application for RGX-121 to treat Mucopolysaccharidosis II, an ultra-rare neurodegenerative d","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4563","BK4505","RGNX"],"gpt_icon":0},{"id":"2610690636","title":"BRIEF-REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II","url":"https://stock-news.laohu8.com/highlight/detail?id=2610690636","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610690636?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:53","pubTimestamp":1770674005,"startTime":"0","endTime":"0","summary":"BRIEF-REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS IIFeb 9 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO ANNOUNCES REGULATORY UPDATE ON RGX-121 BLA FOR MPS IIREGENXBIO INC - FDA ISSUES CO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAZWNLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4563","BK4505","BK4139"],"gpt_icon":0},{"id":"2610661540","title":"Regenxbio falls 21% to $8.10 after FDA issues CRL for BLA for RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2610661540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610661540?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:50","pubTimestamp":1770673819,"startTime":"0","endTime":"0","summary":"16:47 EST Regenxbio (RGNX) falls 21% to $8.10 after FDA issues CRL for BLA for RGX-121 Published first on TheFly – the ultimate source for real-tim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-falls-21-to-8-10-after-fda-issues-crl-for-bla-for-rgx-121-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-falls-21-to-8-10-after-fda-issues-crl-for-bla-for-rgx-121-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4505","BK4588","LU1815336091.USD","CRL","BK4530","IE00BFMHRM44.USD","BK4121","RGNX","LU0757428866.USD","BK4139","LU0029874061.USD","BK4563","BK4585","LU0390134368.USD"],"gpt_icon":0},{"id":"2610166613","title":"US FDA declines to approve Regenxbio's rare disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610166613","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610166613?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:11","pubTimestamp":1770671481,"startTime":"0","endTime":"0","summary":"US FDA declines to approve Regenxbio's rare disease drug Feb 9 (Reuters) - Regenxbio RGNX.O said on Monday the U.S. Food and Drug Administration has declined to approve its drug for a rare disease.  (Reporting by Sneha S K; Editing by Alan Barona) ((Sneha.SK@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nL4N3Z51ZI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4139","BK4505","BK4563"],"gpt_icon":0},{"id":"2610666270","title":"Regenxbio says FDA issues CRL regarding BLA for RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666270","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610666270?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:10","pubTimestamp":1770671428,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) announced that the U.S. FDA has issued a Complete Response Letter regarding its Biologics License Application for RGX-121 for the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-says-fda-issues-crl-regarding-bla-for-rgx-121-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-says-fda-issues-crl-regarding-bla-for-rgx-121-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4530","BK4139","BK4505","CRL","RGNX","LU0390134368.USD","BK4121","LU0757428866.USD","BK4563","BK4588","BK4585","LU0029874061.USD","LU0128526141.USD","IE00BFMHRM44.USD","LU1815336091.USD"],"gpt_icon":0},{"id":"2610666278","title":"REGENXBIO trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610666278?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671158,"startTime":"0","endTime":"0","summary":"16:01 EST REGENXBIO (RGNX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX","BK4505","BK4563","BK4139"],"gpt_icon":0},{"id":"2610665082","title":"Regenxbio Inc - FDA Issues Complete Response Letter for Rgx-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2610665082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610665082?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAZWNLJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4139","BK4563","BK4505"],"gpt_icon":0},{"id":"2610665038","title":"Regenxbio Announces Regulatory Update on Rgx-121 Bla for Mps Ii","url":"https://stock-news.laohu8.com/highlight/detail?id=2610665038","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610665038?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAZWNLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4563","BK4505","BK4139"],"gpt_icon":0},{"id":"2610650886","title":"Regenxbio Inc - Plans to Resubmit Bla for Rgx-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2610650886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610650886?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAZWNLJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","RGNX","BK4505","BK4139"],"gpt_icon":0},{"id":"2610466506","title":"Regenxbio Inc - Requests Type a Meeting With FDA to Discuss Rgx-121 Crl","url":"https://stock-news.laohu8.com/highlight/detail?id=2610466506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610466506?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAZWNLJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4139","BK4505","BK4563"],"gpt_icon":0},{"id":"2610652106","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2610652106","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610652106?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:01","pubTimestamp":1770670860,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nAQN2LLFHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4505","RGNX","BK4139"],"gpt_icon":0},{"id":"2607877110","title":"REGENXBIO Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2607877110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607877110?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:08","pubTimestamp":1769692080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 08:08 ET (13:08 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4505","BK4563"],"gpt_icon":0},{"id":"2607721713","title":"Nippon Shinyaku Partners with REGENXBIO for Exclusive Rights to RGX-111 and RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2607721713","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607721713?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:46","pubTimestamp":1769643988,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL2fP15b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4505","RGNX"],"gpt_icon":0},{"id":"2607774966","title":"FDA Clinical Hold Knocks REGENXBIO Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2607774966","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607774966?lang=en_us&edition=fundamental","pubTime":"2026-01-29 01:31","pubTimestamp":1769621460,"startTime":"0","endTime":"0","summary":"REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to abnormal tissue growth in one patient.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/28/REGENXBIO-Inc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/28/REGENXBIO-Inc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/50199815/fda-clinical-hold-knocks-regenxbio-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/50199815/fda-clinical-hold-knocks-regenxbio-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4563","BK4505","SMA","BK4217","BK4139","RGNX"],"gpt_icon":0},{"id":"2606122327","title":"BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International","url":"https://stock-news.laohu8.com/highlight/detail?id=2606122327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606122327?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:12","pubTimestamp":1769609521,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker InternationalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL6N3YT0MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","GKOS","LU1489326972.SGD","TXN","BROS","OTIS","STEL","GILD","EXTR","VFC","ABBV","QRVO","BK4535","NXT","LU1074936037.SGD","T","DHR","EAT","LU0795875169.SGD","PPG","SBUX","VEON","LU0823431563.USD","TXT","LU1291159041.SGD","LU0314106906.USD","MRK","SARO","LU0211327993.USD","KYIV","FFIV","LU1551013425.SGD","AU","NEM","ELV","LU2430703095.HKD","ADM","IE0009355771.USD","CDE","WIX","LU0320765489.SGD","LU0985481810.HKD","GEV","RGNX","CALC","IE00B894F039.SGD","HL","AI","LU2430703178.SGD"],"gpt_icon":1},{"id":"2606712122","title":"Regenxbio Shares Plunge on FDA Pausing Two Drug Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712122","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712122?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:08","pubTimestamp":1769609280,"startTime":"0","endTime":"0","summary":"Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs after a five-year-old participant in one study developed an intraventricular CNS tumor.The stock fell 33% to $9.02 in pre-market trading Wednesday after closing Tuesday at $13.41. At close, the stock was up 76% over the past 12 months.Regenxbio said Wednesday that the FDA's decision followed preliminary analysis of the tumor, which was observed in a participant in the company's phase 1/2 study of RGX-111 to treat Hurler syndrome, a genetic disease.President and Chief Executive Officer Curran Simpson said the company was surprised by the FDA's decision to pause the RGX-121 program.\"These are separate therapies, and the positive safety profile of RGX-121 in more than 30 patients treated, including those dosed nearly seven years ago, remains unchanged,\" Simpson said. \"Patient safety is our top priority, and we, our investigators, and the patient community remain confid","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Regenxbio Shares Plunge on FDA Pausing Two Drug Development Programs","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4505","BK4139"],"gpt_icon":0},{"id":"2606714456","title":"Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Policy Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714456","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714456?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:49","pubTimestamp":1769608173,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.8% higher in Wednesday's premarket activity, ahead of the Federal O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","XLI","XLF","BETH","US7Y.BOND","IYK","XLY","FAS","IYH","US2Y.BOND","XLP","US10Y.BOND","BITO","SOXX","VHT.AU","US6M.BOND","RGNX","US30Y.BOND","XSD","RTH","XLK","SPY","US3Y.BOND","VIS","IYE","XLE","ASML","UNG","EETH","IYW","US5Y.BOND","US12M.BOND","PB","FAZ","OTIS","RTH.AU","EQR","USO","XLV","VDC","VHT","XRT","STEL","IGM","IYJ","EDU.AU"],"gpt_icon":1},{"id":"2606719765","title":"Regenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719765?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605216,"startTime":"0","endTime":"0","summary":"Regenxbio  said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.Shares of Regenxbio were down more than 30% in recent premarket activity ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","RGNX","BK4563","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":-0.0744},{"period":"1month","weight":-0.3222},{"period":"3month","weight":-0.0785},{"period":"6month","weight":0.3159},{"period":"1year","weight":0.2254},{"period":"ytd","weight":-0.2826}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.091067},{"month":2,"riseRate":0.272727,"avgChangeRate":0.011009},{"month":3,"riseRate":0.6,"avgChangeRate":0.015225},{"month":4,"riseRate":0.6,"avgChangeRate":0.035795},{"month":5,"riseRate":0.3,"avgChangeRate":-0.022478},{"month":6,"riseRate":0.6,"avgChangeRate":0.047674},{"month":7,"riseRate":0.4,"avgChangeRate":-0.001741},{"month":8,"riseRate":0.4,"avgChangeRate":0.017624},{"month":9,"riseRate":0.6,"avgChangeRate":0.07131},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.05132}],"exchange":"NASDAQ","name":"Regenxbio","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regenxbio,RGNX,Regenxbio股票,Regenxbio股票老虎,Regenxbio股票老虎国际,Regenxbio行情,Regenxbio股票行情,Regenxbio股价,Regenxbio股市,Regenxbio股票价格,Regenxbio股票交易,Regenxbio股票购买,Regenxbio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction